Related-Party Transactions

9 Months Ended

Sep. 30, 2025

Related-Party Transactions [Abstract]

Related-Party Transactions

(12)

Related‑Party Transactions

In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 9). The transaction included the issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc (“PharmaCyte”). The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Company’s board of directors. The Series B Warrants expired in November 2024. In November 2024, the Company paid PharmaCyte accrued interest on the convertible note of $300,000 in equity comprising 315,790 common shares.

In conjunction with the June 2025 Financing, certain officers and directors purchased 98,040 common shares in the private placement offering at a price of $1.02 per share.

In conjunction with the August 2025 Financing, certain officers purchased 87,363 common shares at a price of $0.5151 per share.

In addition, for the nine months ended September 30, 2025 and year ended December 31, 2024, a family member of the CEO was employed by the Company.